Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease
| Autor: | Cheng-Jie Mao, Shi-Zhuang Wei, Jin-Bao Zhang, Chen-Tao Wang, Chun-Feng Liu, Yu-Ting Zhang, Dan Li, Chao Ren, Xiao-Yu Yao, An-Qi Dong, Fen Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Parkinson's disease
Pharmacology Dopamine agonist chemistry.chemical_compound Mice Pramipexole Dopamine receptor D3 Dopamine Dopamine receptor D2 Medicine Animals Humans Benzothiazoles Mice Knockout business.industry Depression General Neuroscience MPTP Receptors Dopamine D3 Parkinson Disease medicine.disease chemistry Knockout mouse Dopamine Agonists Quality of Life business medicine.drug |
| Zdroj: | Brain research bulletin. 177 |
| ISSN: | 1873-2747 |
| Popis: | Depression is one of the strongest predictors of quality of life in patients with Parkinson’s disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2−/− mice but not in DRD3−/− mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect